The Brain and Spine Institute is made up of experts in the field of neuroscience in order to bring patients the best healthcare in East Tennessee for a full range of neurological diseases and disorders.
myClipboard
myClipboard
Save news, events, articles and doctor's information to your personal clipboard for later reference.
Add items by clicking the
button.
The Brain and Spine Institute is made up of experts in the field of neuroscience in order to bring patients the best healthcare in East Tennessee for a full range of neurological diseases and disorders.
We provide a comprehensive continuum of cancer services, including prevention, outreach, diagnostic, treatment and support services delivered by our highly skilled staff with compassion and care.
The Center for Women & Children's Health is a hub for supporting women's and children's individual healthcare needs. The center provides support, research and unmatched patient-centered care.
Emergency and Trauma Services is the only Level I Trauma Center in the area and serves as the tertiary referral center for medical care in East Tennessee, serving Knox County and 21 surrounding counties.
The Heart Lung Vascular Institute brings together expertise in clinical care, teaching and research. Patients receive exceptional healthcare combined with patient-centered care.

Retinal vein occlusion is a blockage of the small veins that carry blood away from the retina. The retina is the layer of tissue at the back of the inner eye that converts light images to nerve signals and sends them to the brain.
Central retinal vein occlusion; Branch retinal vein occlusion; CRVO; BRVO
Retinal vein occlusion is most often caused by hardening of the arteries (atherosclerosis) and the formation of a blood clot.
Blockage of smaller veins (branch veins or BRVO) in the retina often occurs when retinal arteries that have been thickened or hardened by atherosclerosis cross over and place pressure on a retinal vein.
Rick factors for retinal vein occlusion include:
Because the risk of these disorders increases with age, retinal vein occlusion most often affects older people.
Blockage of retinal veins may cause other eye problems, including:
Tests to evaluate for vein occlusion include:
Other tests may include:
The health care provider should closely monitor any blockage for several months. Many harmful effects, such as glaucoma, take 3 or more months to develop after the occlusion.
Many people will regain vision, even without treatment. However, vision rarely returns to normal. There is no way to reverse or open the blockage.
You may need treatment to prevent another blockage from forming in the same or the other eye.
It's important to manage diabetes, high blood pressure, and high cholesterol levels. Some patients may receive aspirin or other blood thinners.
Treatment for the complications of retinal vein occlusion may include:
The outcome varies. Patients with retinal vein occlusion often regain useful vision.
It is important to properly manage complications, such as macular edema and glaucoma. However, having either of these complications is more likely to lead to a poor outcome.
Call your health care provider if you have sudden blurring or vision loss.
Retinal vein occlusion is a sign of a general blood vessel (vascular) disease. The same measures used to prevent other blood vessel diseases, such as coronary artery disease, may decrease the risk of retinal vein occlusion.
These measures include:
Aspirin or other blood thinners may help prevent blockages in the other eye.
Controlling diabetes is important in general, and it may also be helpful for preventing retinal vein occlusion.
Sanborn GE, Magargal LE. Venous occlusive disease of the eye. In: Tasman W, Jaeger EA, eds. Duane's Ophthalmology. 15th ed. Philadelphia, Pa: Lippincott, Williams & Wilkins: 2009:chap 15.
Wu L, Arevalo JF, Roca JA, Maia M, Berrocal MH, Rodriguez FJ, et al. Pan-American Collaborative Retina Study Group (PACORES). Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina. 2008;28:212-219.
Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2008;92:351-355.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).